Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Private Equity Firm
Pharma
Bluebird investor reluctance pays off with better buyout offer
Bluebird bio investors are now offered an option to bag $5 per share in cash, an alternative to the original upfront-plus-CVR deal structure.
Angus Liu
May 14, 2025 10:40am
Bluebird warns of potential bankruptcy amid buyout delay
May 13, 2025 9:56am
Bain Capital lays out $3.3B to acquire Mitsubishi Tanabe Pharma
Feb 7, 2025 11:26am
Grifols deflects private equity firm's potential takeover offer
Nov 20, 2024 10:13am
CDMO Avid to go private in $1.1B deal
Nov 7, 2024 2:50pm
Nektar extends cash runway with $90M manufacturing plant sale
Nov 4, 2024 1:16pm
